The Growth Suppressor PML Represses Transcription by Functionally and Physically Interacting with Histone Deacetylases

ABSTRACT The growth suppressor promyelocytic leukemia protein (PML) is disrupted by the chromosomal translocation t(15;17) in acute promyelocytic leukemia (APL). PML plays a key role in multiple pathways of apoptosis and regulates cell cycle progression. The present study demonstrates that PML represses transcription by functionally and physically interacting with histone deacetylase (HDAC). Transcriptional repression mediated by PML can be inhibited by trichostatin A, a specific inhibitor of HDAC. PML coimmunoprecipitates a significant level of HDAC activity in several cell lines. PML is associated with HDAC in vivo and directly interacts with HDAC in vitro. The fusion protein PML-RARα encoded by the t(15;17) breakpoint interacts with HDAC poorly. PML interacts with all three isoforms of HDAC through specific domains, and its expression deacetylates histone H3 in vivo. Together, the results of our study show that PML modulates histone deacetylation and that loss of this function in APL alters chromatin remodeling and gene expression. This event may contribute to the development of leukemia.

[1]  P. Chambon,et al.  PMLRAR homodimers: distinct DNA binding properties and heteromeric interactions with RXR. , 1993, The EMBO journal.

[2]  R. Evans,et al.  Localization of nascent RNA and CREB binding protein with the PML-containing nuclear body. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[3]  S. Schreiber,et al.  A role for histone deacetylase activity in HDAC1-mediated transcriptional repression. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[4]  Andrew J. Bannister,et al.  The TAFII250 Subunit of TFIID Has Histone Acetyltransferase Activity , 1996, Cell.

[5]  E. Brignole,et al.  Disruption of PML Subnuclear Domains by the Acidic IE1 Protein of Human Cytomegalovirus Is Mediated through Interaction with PML and May Modulate a RING Finger-Dependent Cryptic Transactivator Function of PML , 1998, Molecular and Cellular Biology.

[6]  C. Sherr.  G1 phase progression: Cycling on cue , 1994, Cell.

[7]  R. Eisenman,et al.  Mad-max transcriptional repression is mediated by ternary complex formation with mammalian homologs of yeast repressor Sin3 , 1995, Cell.

[8]  P. Pandolfi,et al.  Pml is essential for multiple apoptotic pathways , 1998, Nature Genetics.

[9]  T. Kouzarides,et al.  Modulation of Fos-mediated AP-1 transcription by the promyelocytic leukemia protein , 1998, Oncogene.

[10]  Peirong Yang,et al.  Analysis of the Growth and Transformation Suppressor Domains of Promyelocytic Leukemia Gene, PML(*) , 1996, The Journal of Biological Chemistry.

[11]  Wen‐Ming Yang,et al.  Histone Deacetylases Associated with the mSin3 Corepressor Mediate Mad Transcriptional Repression , 1997, Cell.

[12]  E. Yeh,et al.  Identification of Three Major Sentrinization Sites in PML* , 1998, The Journal of Biological Chemistry.

[13]  I. Weissman,et al.  A PMLRARα transgene initiates murine acute promyelocytic leukemia , 1997 .

[14]  M. Vettese-Dadey,et al.  Acetylation of histone H4 plays a primary role in enhancing transcription factor binding to nucleosomal DNA in vitro. , 1996, The EMBO journal.

[15]  C. Peschle,et al.  Promyelocytic leukemia-specific PML-retinoic acid alpha receptor fusion protein interferes with erythroid differentiation of human erythroleukemia K562 cells. , 1995, Cancer research.

[16]  T. Kouzarides,et al.  Transcriptional repression by the promyelocytic leukemia protein, PML. , 1997, Experimental cell research.

[17]  E. Wintersberger,et al.  Interaction of Sp1 with the growth- and cell cycle-regulated transcription factor E2F , 1996, Molecular and cellular biology.

[18]  C. Tribioli,et al.  Acute leukemia with promyelocytic features in PML/RARalpha transgenic mice. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[19]  G. Hayward,et al.  The major immediate-early proteins IE1 and IE2 of human cytomegalovirus colocalize with and disrupt PML-associated nuclear bodies at very early times in infected permissive cells , 1997, Journal of virology.

[20]  Tony Kouzarides,et al.  Retinoblastoma protein recruits histone deacetylase to repress transcription , 1998, Nature.

[21]  Christine Chomienne,et al.  The PML-RARα fusion mRNA generated by the t(15;17) translocation in acute promyelocytic leukemia encodes a functionally altered RAR , 1991, Cell.

[22]  P. Robbins,et al.  The Retinoblastoma Susceptibility Gene Product Represses Transcription When Directly Bound to the Promoter (*) , 1995, The Journal of Biological Chemistry.

[23]  D. Sheer,et al.  Molecular analysis of acute promyelocytic leukemia breakpoint cluster region on chromosome 17. , 1990, Science.

[24]  M. Hung,et al.  Recombinant PML adenovirus suppresses growth and tumorigenicity of human breast cancer cells by inducing G1 cell cycle arrest and apoptosis , 1998, Oncogene.

[25]  M. Grunstein.  Histone acetylation in chromatin structure and transcription , 1997, Nature.

[26]  G. Lozano,et al.  PML, a growth suppressor disrupted in acute promyelocytic leukemia , 1994, Molecular and cellular biology.

[27]  T. Sternsdorf,et al.  Evidence for Covalent Modification of the Nuclear Dot–associated Proteins PML and Sp100 by PIC1/SUMO-1 , 1997, The Journal of cell biology.

[28]  B. Howard,et al.  The Transcriptional Coactivators p300 and CBP Are Histone Acetyltransferases , 1996, Cell.

[29]  Myriam Alcalay,et al.  The acute promyelocytic leukemia-specific PML-RARα fusion protein inhibits differentiation and promotes survival of myeloid precursor cells , 1993, Cell.

[30]  M. Grunstein,et al.  HDA1 and HDA3 Are Components of a Yeast Histone Deacetylase (HDA) Complex* , 1996, The Journal of Biological Chemistry.

[31]  X. Le,et al.  Stable overexpression of PML alters regulation of cell cycle progression in HeLa cells. , 1997, Carcinogenesis.

[32]  M. Pazin,et al.  What's Up and Down with Histone Deacetylation and Transcription? , 1997, Cell.

[33]  Wei-Wei Zhang,et al.  Cell-cycle regulation of DNA damage-induced expression of the suppressor gene PML. , 1997, Biochemical and biophysical research communications.

[34]  R. Rousset,et al.  Exclusion of Int-6 from PML Nuclear Bodies by Binding to the HTLV-I Tax Oncoprotein , 1996, Science.

[35]  P. Pandolfi,et al.  Arsenic trioxide and melarsoprol induce programmed cell death in myeloid leukemia cell lines and function in a PML and PML-RARalpha independent manner. , 1998, Blood.

[36]  E. Dmitrovsky,et al.  Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid). , 1991, The New England journal of medicine.

[37]  C. Peschle,et al.  Arsenic trioxide as an inducer of apoptosis and loss of PML/RAR alpha protein in acute promyelocytic leukemia cells. , 1998, Journal of the National Cancer Institute.

[38]  E. Yeh,et al.  Covalent Modification of PML by the Sentrin Family of Ubiquitin-like Proteins* , 1998, The Journal of Biological Chemistry.

[39]  Andrew J. Bannister,et al.  The CBP co-activator is a histone acetyltransferase , 1996, Nature.

[40]  A. Wolffe,et al.  Histone acetyltransferases in control. , 1997, Current biology : CB.

[41]  C. Van Lint,et al.  Characterization of a human RPD3 ortholog, HDAC3. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[42]  K. Umesono,et al.  Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RARα with a novel putative transcription factor, PML , 1991, Cell.

[43]  Maria Carmo-Fonseca,et al.  Retinoic acid regulates aberrant nuclear localization of PML-RARα in acute promyelocytic leukemia cells , 1994, Cell.

[44]  M. Koken,et al.  PML induces a novel caspase-independent death process , 1998, Nature Genetics.

[45]  J. Broach,et al.  Transcriptional silencing in yeast is associated with reduced nucleosome acetylation. , 1993, Genes & development.

[46]  P. Pandolfi,et al.  Role of PML in cell growth and the retinoic acid pathway. , 1998, Science.

[47]  M. Weitzman,et al.  Adenovirus replication is coupled with the dynamic properties of the PML nuclear structure. , 1996, Genes & development.

[48]  S. Ōmura,et al.  Accelerated degradation of PML-retinoic acid receptor alpha (PML-RARA) oncoprotein by all-trans-retinoic acid in acute promyelocytic leukemia: possible role of the proteasome pathway. , 1996, Cancer Research.

[49]  I. Weissman,et al.  A PMLRARalpha transgene initiates murine acute promyelocytic leukemia. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[50]  Wei Tang,et al.  Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. , 1997, Blood.

[51]  C. Tribioli,et al.  Acute leukemia with promyelocytic features in PML/RARα transgenic mice , 1997 .

[52]  A. Dejean,et al.  Molecular Cloning of a New Interferon-induced PML Nuclear Body-associated Protein* , 1997, The Journal of Biological Chemistry.

[53]  M. Andreeff,et al.  The PML gene encodes a phosphoprotein associated with the nuclear matrix. , 1995, Blood.

[54]  R. Everett,et al.  HSV‐1 IE protein Vmw110 causes redistribution of PML. , 1994, The EMBO journal.

[55]  C. Tribioli,et al.  Distinct interactions of PML-RARα and PLZF-RARα with co-repressors determine differential responses to RA in APL , 1998, Nature Genetics.

[56]  K. Chang,et al.  PML suppresses oncogenic transformation of NIH/3T3 cells by activated neu , 1995, The Journal of experimental medicine.

[57]  Shiaw-Yih Lin,et al.  Cell cycle-regulated association of E2F1 and Sp1 is related to their functional interaction , 1996, Molecular and cellular biology.

[58]  Ya-Li Yao,et al.  Isolation and Characterization of cDNAs Corresponding to an Additional Member of the Human Histone Deacetylase Gene Family* , 1997, The Journal of Biological Chemistry.

[59]  C. Tribioli,et al.  Distinct interactions of PML-RARalpha and PLZF-RARalpha with co-repressors determine differential responses to RA in APL. , 1998, Nature genetics.

[60]  E. Milgrom,et al.  Effect of PML and PML-RAR on the transactivation properties and subcellular distribution of steroid hormone receptors. , 1995, Molecular endocrinology.

[61]  T. Ley,et al.  Altered myeloid development and acute leukemia in transgenic mice expressing PML-RAR alpha under control of cathepsin G regulatory sequences. , 1997, Blood.

[62]  D. Dean,et al.  Rb Interacts with Histone Deacetylase to Repress Transcription , 1998, Cell.

[63]  J M Davies,et al.  Leukemia-associated retinoic acid receptor alpha fusion partners, PML and PLZF, heterodimerize and colocalize to nuclear bodies. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[64]  S. Inoue,et al.  Role of the histone deacetylase complex in acute promyelocytic leukaemia , 1998, Nature.

[65]  L. Szekely,et al.  The Epstein-Barr virus-encoded nuclear antigen EBNA-5 accumulates in PML-containing bodies , 1996, Journal of virology.

[66]  Alan P. Wolffe,et al.  A positive role for histone acetylation in transcription factor access to nucleosomal DNA , 1993, Cell.

[67]  K. Struhl.  Histone acetylation and transcriptional regulatory mechanisms. , 1998, Genes & development.

[68]  Christopher K. Glass,et al.  The transcriptional co-activator p/CIP binds CBP and mediates nuclear-receptor function , 1997, Nature.

[69]  L. Magnaghi-Jaulin,et al.  Retinoblastoma protein represses transcription by recruiting a histone deacetylase , 1998, Nature.

[70]  S. Minucci,et al.  Fusion proteins of the retinoic acid receptor-α recruit histone deacetylase in promyelocytic leukaemia , 1998, Nature.

[71]  P. Freemont,et al.  PIC 1, a novel ubiquitin-like protein which interacts with the PML component of a multiprotein complex that is disrupted in acute promyelocytic leukaemia. , 1996, Oncogene.

[72]  C. Niu,et al.  Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): I. As2O3 exerts dose-dependent dual effects on APL cells. , 1997, Blood.

[73]  S. Schreiber,et al.  Nuclear Receptor Repression Mediated by a Complex Containing SMRT, mSin3A, and Histone Deacetylase , 1997, Cell.

[74]  L. Chung,et al.  Adenovirus-mediated expression of PML suppresses growth and tumorigenicity of prostate cancer cells. , 1997, Cancer research.

[75]  R. Evans,et al.  A novel macromolecular structure is a target of the promyelocyte-retinoic acid receptor oncoprotein , 1994, Cell.

[76]  A. Dejean,et al.  Conjugation with the ubiquitin‐related modifier SUMO‐1 regulates the partitioning of PML within the nucleus , 1998, The EMBO journal.

[77]  Jennifer O'Neil,et al.  Sequestration and Inhibition of Daxx-Mediated Transcriptional Repression by PML , 2000, Molecular and Cellular Biology.

[78]  L. Szekely,et al.  The Promyelocytic Leukemia Gene Product (PML) Forms Stable Complexes with the Retinoblastoma Protein , 1998, Molecular and Cellular Biology.

[79]  L. Deaven,et al.  Characterization of a fusion cDNA (RARA/myl) transcribed from the t(15;17) translocation breakpoint in acute promyelocytic leukemia , 1992, Molecular and cellular biology.

[80]  K. Chang,et al.  The Promyelocytic Leukemia Protein Interacts with Sp1 and Inhibits Its Transactivation of the Epidermal Growth Factor Receptor Promoter , 1998, Molecular and Cellular Biology.